CClinicalTrials.gg
Not yet recruitingNCT07598162Updated May 20, 2026

RLB vs ERSP for Postoperative Analgesia in Lap Cholecystectomy

An interventional study of Retrolaminar Block (RLB) and Erector spinae plane block (ESPB) in Laparoscopic Cholecystectomy Surgery Postoperative Analgesia, sponsored by Sohag University. Not yet recruiting at 1 site in Egypt. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-05-20.

Sponsored by Sohag University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
20 Years to 60 Years
Sex
All
01

Study summary

This prospective, randomized, double-blind clinical trial evaluates the comparative effectiveness of ultrasound-guided retrolaminar block (RLB) and erector spinae plane block (ESPB) for postoperative analgesia in patients undergoing laparoscopic cholecystectomy. A total of 100 ASA I-II patients, aged 20-60 years, will be randomly allocated into two equal groups to receive either RLB or ESPB bilaterally following induction of standardized general anesthesia. The primary outcome is the time to first request for rescue analgesia, while secondary outcomes include total morphine consumption within the first 24 hours, postoperative pain scores assessed using the Numeric Rating Scale (NRS), patient satisfaction, and the incidence of adverse events. Pain assessment will be performed at predefined intervals over the first 24 hours postoperatively. The study aims to determine which technique provides superior analgesia with reduced opioid requirements and improved patient outcomes.

02

Conditions studied

  • Laparoscopic Cholecystectomy Surgery Postoperative Analgesia
03

In context

Lead sponsor

Sohag University is the lead sponsor of 1,183 studies on the registry; 612 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

    • Age from 20 to 60 years.

      • Both sexes.
      • American Society of Anesthesiology (ASA) grade I and II physical status.
      • Patients will undergo cholecystectomy under general anesthesia.

Exclusion criteria

Exclusion Criteria:

    • Sensitivities or contraindications to the study medications.

      • Infection at the site of injection.
      • Emergency surgery.
      • Body mass index (BMI) > 35.
      • Organic comorbidities.
      • Histories of psychological conditions and/or chronic pain syndromes.
      • Contraindications to regional anesthesia.
      • Severe respiratory, cardiac, hepatic and renal disorders.
      • Pregnancy.
      • Coagulopathy.
      • Opioid addiction.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    RLB group

    Biological: Retrolaminar Block (RLB)

  • Active comparator
    ESPB group

    Procedure: Erector spinae plane block (ESPB)

Interventions

  • BiologicalRetrolaminar Block (RLB)

    Patients will be positioned laterally, and a curved ultrasound probe will be aligned longitudinally at the T7 vertebra. The vertebral lamina and spinous process will be identified. A needle will be inserted 1 - 1.5 cm lateral to the spinous process, advanced toward the lamina, and 20 mL of LA mixture will be injected into the fascial plane between the lamina and transversus spinae muscles bilaterally.

  • ProcedureErector spinae plane block (ESPB)

    The blocks will be conducted at the level of the T7 spinous process (SP) with the patient in the lateral position and the arm abducted. Using US ( curved probe ) , the T7 transverse process (TP) is identified by counting from the 12th rib. The US probe is positioned 2 - 3 cm laterally to the SP of T7 and situated over the TP of T7/T8 in the parasagittal longitudinal plane, with the erector spinae muscle (ESM) visualized over the TP. The needle is then inserted and advanced in plane from cephalad to caudad until the needle tip contacts the TP of T7. Following hydro dissection with 2 mL of isotonic saline, which elevates the ESM, 20 mL of LA mixture is administered after several negative aspirations.

06

What researchers measure

Primary outcomes

  1. Time to the 1st rescue analgesia

    Time frame: in the 1st 24hr.

Secondary outcomes

  1. Total morphine consumption

    Time frame: in the 1st 24hr.

  2. Pain score.

    postoperative pain assessment with the Numeric Rating Scale (NRS). Numeric rating scale .. zero represents no pain while 10 represents the worst pain imaginable

    Time frame: Pain will be assessed at, 2, 4, 6, 8, 12, 18 and 24 hour postoperatively.

  3. Degree of patient satisfaction

    • Degree of patient satisfaction will be assessed on a 5-point Likert scale patient satisfaction (1 represents extremely dissatisfied 2 represesnts unsatisfied; 3 represents neutral 4 represents satisfied 5 represents extremely satisfied)

    Time frame: in the first 24 hours after surgery

07

Study locations

1 site
  • Sohag Faculty of Medicine
    Sohag, Egypt
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07598162
Lead sponsor
Sohag University
Responsible party
Esraa Abdallah Mohamed (Resident of Anesthesia, Surgical Intensive Care and Pain Management Faculty of Medicine, Sohag University, Sohag University) — Principal investigator
First posted
May 20, 2026
Start date
Apr 2026 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
May 20, 2026

Study contacts

Esraa abdallah Mohamed, resident
Contact
esraa97egy@gmail.com
01066981675

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion